AI Article Synopsis
- Programmed cell death protein-1 (PD-1) is an important immune checkpoint that is affected by various post-translational modifications, influencing its behavior and interactions within the immune system.
- Recent studies have focused on specific types of these modifications, such as ubiquitination and glycosylation, to understand their role in PD-1's function and how they might be targeted for new therapies.
- Current immunotherapies targeting PD-1/PD-L1 only benefit a portion of patients (35-45%), highlighting the need for innovative approaches that address the challenges faced by non-responders to these treatments.
Article Abstract
Programmed cell death protein-1 (PD-1) is a vital immune checkpoint molecule. The location, stability, and protein-protein interaction of PD-1 are significantly influenced by post-translational modification (PTM) of proteins. The biological information of PD-1, including its gene and protein structures and the PD-1/PD-L1 signaling pathway, was briefly reviewed in this review. Additionally, recent research on PD-1 post-translational modification, including the study of ubiquitination, glycosylation, phosphorylation, and palmitoylation, was summarized, and research strategies for PD-1 PTM drugs were concluded. At present, only a part of PD-1/PD-L1 treated patients (35-45%) are benefited from immunotherapies, and novel strategies targeting PTM of PD-1/PD-L1 may be important for anti-PD-1/PD-L1 non-responders (poor responders).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10968922 | PMC |
| http://dx.doi.org/10.3390/cimb46030136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!